NXTC vs. AUPH

Last updated Apr 2, 2026

Compare and contrast key facts about NextCure, Inc. (NXTC) and Aurinia Pharmaceuticals Inc. (AUPH).

Performance

NXTC vs. AUPH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in NextCure, Inc. (NXTC) and Aurinia Pharmaceuticals Inc. (AUPH). The values are adjusted to include any dividend payments, if applicable.

NXTC vs. AUPH - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
NXTC NextCure, Inc.	-25.79%	53.37%	-32.37%	-19.15%	-76.50%	-44.95%	-80.65%	183.07%
AUPH Aurinia Pharmaceuticals Inc.	-3.01%	77.62%	-0.11%	108.10%	-81.11%	65.37%	-31.74%	229.43%

Fundamentals

EPS NXTC : -$22.97 AUPH : $2.06
Total Revenue (TTM) NXTC : $0.00 AUPH : $283.06M
Gross Profit (TTM) NXTC : $0.00 AUPH : $250.39M
EBITDA (TTM) NXTC : -$57.50M AUPH : $109.83M

Returns By Period

In the year-to-date period, NXTC achieves a -25.79% return, which is significantly lower than AUPH's -3.01% return.

NXTC

• 1D: -1.40%
• 1M: -15.89%
• YTD: -25.79%
• 6M: 85.06%
• 1Y: 100.80%
• 3Y*: -15.99%
• 5Y*: -38.63%
• 10Y*: —

AUPH

• 1D: 4.39%
• 1M: 8.87%
• YTD: -3.01%
• 6M: 35.70%
• 1Y: 92.17%
• 3Y*: 12.17%
• 5Y*: 3.32%
• 10Y*: 18.02%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NXTC vs. AUPH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NXTC

NXTC Risk / Return Rank: 73
NXTC Sharpe Ratio Rank: 72
NXTC Sortino Ratio Rank: 75
NXTC Omega Ratio Rank: 75
NXTC Calmar Ratio Rank: 76
NXTC Martin Ratio Rank: 69

AUPH

AUPH Risk / Return Rank: 91
AUPH Sharpe Ratio Rank: 90
AUPH Sortino Ratio Rank: 88
AUPH Omega Ratio Rank: 88
AUPH Calmar Ratio Rank: 95
AUPH Martin Ratio Rank: 92

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NXTC vs. AUPH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for NextCure, Inc. (NXTC) and Aurinia Pharmaceuticals Inc. (AUPH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NXTC	AUPH	Difference
Sharpe ratio Return per unit of total volatility	0.96	2.04	-1.09
Sortino ratio Return per unit of downside risk	1.91	2.66	-0.75
Omega ratio Gain probability vs. loss probability	1.26	1.38	-0.12
Calmar ratio Return relative to maximum drawdown	1.97	5.81	-3.84
Martin ratio Return relative to average drawdown	3.46	12.66	-9.19
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NXTC vs. AUPH - Sharpe Ratio Comparison

The current NXTC Sharpe Ratio is 0.96, which is lower than the AUPH Sharpe Ratio of 2.04. The chart below compares the historical Sharpe Ratios of NXTC and AUPH, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NXTC	AUPH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.96	2.04	-1.09
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.53	0.05	-0.57
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.24	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.29	0.17	-0.46

Correlation

The correlation between NXTC and AUPH is 0.24, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NXTC vs. AUPH - Dividend Comparison

Neither NXTC nor AUPH has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NXTC vs. AUPH - Drawdown Comparison

The maximum NXTC drawdown since its inception was -99.71%, which is greater than AUPH's maximum drawdown of -87.58%. Use the drawdown chart below to compare losses from any high point for NXTC and AUPH.

Drawdown Indicators

	NXTC	AUPH	Difference
Max Drawdown Largest peak-to-trough decline	-99.71%	-87.58%	-12.13%
Max Drawdown (1Y) Largest decline over 1 year	-42.00%	-15.91%	-26.09%
Max Drawdown (5Y) Largest decline over 5 years	-97.37%	-87.58%	-9.79%
Max Drawdown (10Y) Largest decline over 10 years	—	-87.58%	—
Current Drawdown Current decline from peak	-99.05%	-53.23%	-45.82%
Average Drawdown Average peak-to-trough decline	-86.30%	-49.17%	-37.13%
Ulcer Index Depth and duration of drawdowns from previous peaks	23.88%	7.30%	+16.58%

Volatility

NXTC vs. AUPH - Volatility Comparison

NextCure, Inc. (NXTC) has a higher volatility of 22.87% compared to Aurinia Pharmaceuticals Inc. (AUPH) at 13.51%. This indicates that NXTC's price experiences larger fluctuations and is considered to be riskier than AUPH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NXTC	AUPH	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.87%	13.51%	+9.36%
Volatility (6M) Calculated over the trailing 6-month period	80.79%	26.87%	+53.92%
Volatility (1Y) Calculated over the trailing 1-year period	106.45%	45.40%	+61.05%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	73.66%	68.71%	+4.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	124.34%	74.42%	+49.92%

Financials